Affimed (AFMD) Stock Price, News & Analysis

Company Overview

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States and Germany. The company's lead product candidates include AFM13 that has completed Phase 2 clinical trial for CD30-positive lymphoma, Phase Ib clinical trial for hodgkin lymphoma, and completed Phase IIb clinical study for peripheral T-cell lymphoma; AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; and AFM28, an innate cell engager (ICE), which is in preclinical development for the treatment acute myeloid. It develops AFM32, an ICE candidate that is in preclinical development for the treatment of solid tumors. It has collaboration with Artiva Biotherapeutics to develop the combination of acimtamig and AlloNK; license and strategic collaboration agreement with Roivant Sciences Ltd. to develop and commercialize novel ICE molecules, including AFM32, in oncology; and strategic collaboration agreement with Genentech for the development of certain product candidates, which includes novel NK cell engager-based immunotherapeutics to treat multiple cancers. The company was formerly known as Affimed Therapeutics B.V. and changed its name to Affimed N.V. in October 2014. Affimed N.V. was founded in 2000 and is headquartered in Mannheim, Germany.

Key Stats

• Today's Range: $0.18 to $0.18
• 50-Day Range: $0.09 to $0.83
• 52-Week Range: $0.07 to $1.13
• Volume: N/A
• Average Volume: 51.16 million shs
• Market Capitalization: $2.92 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $0.25
• Consensus Rating: Hold

AFMD Stock Analysis - Frequently Asked Questions

How were Affimed's earnings last quarter?

Affimed (NASDAQ:AFMD) released its quarterly earnings data on Wednesday, November, 10th. The biopharmaceutical company reported ($1.40) earnings per share for the quarter, missing the consensus estimate of ($1.30) by $0.10. The biopharmaceutical company earned $10.21 million during the quarter, compared to analyst estimates of $11.79 million. Affimed had a negative net margin of 7,836.26% and a negative trailing twelve-month return on equity of 193.84%.
Read the conference call transcript.

When did Affimed's stock split?

Shares of Affimed reverse split on the morning of Monday, March 11th 2024.The 1-10 reverse split was announced on Wednesday, March 6th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Friday, March 8th 2024. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

When did Affimed IPO?

Affimed (AFMD) raised $96 million in an IPO on Friday, September 12th 2014. The company issued 8,000,000 shares at a price of $11.00-$13.00 per share.

What other stocks do shareholders of Affimed own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Affimed investors own include Meta Platforms (META), NVIDIA (NVDA), Novavax (NVAX), Tesla (TSLA), Advanced Micro Devices (AMD), Plug Power (PLUG) and Sorrento Therapeutics (SRNE).

Company Calendar

• Last Earnings: 11/10/2021
• Today: 5/05/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:AFMD
• CIK: 1608390
• Web: www.affimed.com
• Phone: 496221674360
• Fax: 49-6221-653-0777
• Employees: 200
• Year Founded: 2000

Price Target and Rating

• Average Price Target for Affimed: $0.25
• High Price Target: $0.39
• Low Price Target: $0.10
• Potential Upside/Downside: +35.0%
• Consensus Rating: Hold
• Rating Score (0-4): 2.00
• Research Coverage: 4 Analysts

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$114.66 million
• Net Margins: -7,836.26%
• Pretax Margin: -7,837.50%
• Return on Equity: -193.84%
• Return on Assets: -107.24%

Debt

• Debt-to-Equity Ratio: 0.13
• Current Ratio: 1.93
• Quick Ratio: 1.93

Sales & Book Value

• Annual Sales: $877 thousand
• Price / Sales: 3.33
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $4.19 per share
• Price / Book: 0.04

Miscellaneous

• Outstanding Shares: 16,100,000
• Free Float: 15,488,000
• Market Cap: $2.92 million
• Optionable: No Data
• Beta: 2.07